• NEWS & PRESS
  • pressReleases
  • newsMedia
  • CAREERS
  • Career Openings
  • CONTACT US
  • EXCELLENT RESEARCH

    AND DEVELOPMENT CAPABILITIES

    ROBUST R&D ENGINE

    We have established a robust R&D engine, driven by our world-class team with a track record of prolific drug discovery, as well as a rigorous approach to discover novel and high-quality molecules by leveraging our multi-dimensional innovation-driving discovery platform.

    ——  bobapp下载地址_bob客户端下载_bob直播平台

    01---
    02---

    Founders

    -------------------------------------------------

    Seasoned management team led by visionary founders with a proven track record of drug innovation and development, and backed by blue chip investors

    Dr. Yaochang Xu
    Founder & CEO
    Dr. Yaochang Xu
    Founder & CEO
    Dr. Yao-Chang Xu has more than 25 years of drug dis...
    Dr. Hongping Yu
    Senior VP and co-founder, Head of Chemistry
    Dr. Hongping Yu
    Senior VP and co-founder, Head of Chemistry
    Dr. Hongping Yu has worked in drug discovery and de...
    Dr. Zhui Chen
    Senior VP and co-founder, Head of Biology
    Dr. Zhui Chen
    Senior VP and co-founder, Head of Biology
    Dr. Zhui Chen is a seasoned biologist and drug hunt...
    We address the large oncology market in China and globally.
    Leveraging our robust in-house R&D capabilities, we have developed a rich pipeline of clinical and pre-clinical stage drug candidates

    Our mission

    -------------------------------------------------

    The discovery, Development, And Clinical Verification

    We are committed to focus on discovery of next-generation candidates with improved efficacy and safety and low risks, so that patients can benefit as soon as possible.

    We strategically focus

    small molecule precision oncology therapies & small molecule immuno-oncology therapies

    Our Pipeline

    Consists of a broad range of small-molecule
    precision-oncology and immuno-oncology product candidates

    Partnership

    Excellent cooperation model and relationship

    News & Press

    OUR VISION

    We aspire to become a leading biopharmaceutical company that discovers and develops novel, differentiated therapies in cancer and beyond, addressing critical unmet needs for patients in China and globally.

    Investors

    Abbisko's investors including internationally renowned venture capital companies and domestic healthcare leaders provide support for the company's growth.

    Tel:(+86) 021-68912098

    E-MailL:Public@abbisko.com Bd@abbisko.com

    Copyright © 2021 All rights reserved:Abbisko Therapeautics     HuICP: 17056565-1   

    {{currentdata.name}}
    {{currentdata.post}}